The global Women’s Health market size was estimated at USD 38.12 billion in 2021 and is expected to surpass around USD 58.25 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.10% during the forecast period 2022 to 2030. Market growth can be attributed to the increase in the women geriatric population and the introduction of new products for women’s health, such as Relugoliz and Orilissa among others. Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive the market over the forecast period. The market exhibited lower than the expected growth during the pandemic.
Access to contraception and gynecological testing declined, raising the rate of unsafe abortions and unwanted pregnancies, especially in developing countries. For instance, according to the BMC, in the low- and middle-income countries, there has been around a 10% decline in the use of long- and short-acting reversible contraceptives, about 10% decline in essential services related to pregnancy care. All these factors led to a decline in market growth amid the pandemic. Women are more susceptible to various diseases, such as osteoporosis, osteoarthritis, endometriosis, and menstrual health disorders.
Around 73% of postmenopausal women experience hot flashes, fatigue, and sleep disturbances, which increase dependence on medications, impairing the quality of life. With aging and the increasing prevalence of obesity, the cases of osteoporosis are anticipated to grow. Some of the major factors leading to hormonal imbalance in women are stress, change in dietary habits, and alcohol consumption, which further cause fertility issues. Polycystic Ovarian Syndrome (PCOS), ovulation problems, and endometriosis are some of the major causes of infertility. According to the WHO, in 2021, globally, around 190 million women of reproductive age were affected by endometriosis.
These factors are anticipated to fuel the market growth. According to the United Nations, the Department of Social and Economic Affairs, approximately 1.1 billion women needed family planning in 2019, out of which, 190 million had unmet contraception needs and about 842 million used modern methods of contraception. Owing to the high unmet need for publicly-funded contraceptive services and products, federal & state governments are actively working toward improving family planning services and improving access to modern contraceptives.
For instance, in 2020, Germany’s total multilateral funding for sexual & reproductive and family planning was around USD 121.85 million, an increase of about 65% from 2019. Furthermore, agencies, such as USAID run reproductive health & family planning programs in more than 30 countries, including South Africa & other African countries, where there is a high unmet need for contraception. However, there are various complications and adverse effects of prolonged use of contraceptives, which lead to an increase in the adoption of traditional contraceptive methods.
Report Scope of the Women’s Health Market
|
Report Coverage |
Details |
|
Market Size |
US$ 58.25 Billion by 2030 |
|
Growth Rate |
CAGR of 4.10% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Treatment Type ,Disease Indication and Region, |
|
Companies Mentioned |
AbbVie, Inc.; Bayer AG; Merck & Co., Inc.; Pfizer, Inc; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc; Apothecus Pharmaceutical Corp.; Blairex Laboratories, Inc.; Ferring B.V. |
Some socio-cultural factors holding women back from being benefitted from various quality health services and attaining good health include the following:
The global women’s health market is likely to be adversely impacted by the ongoing outbreak of coronavirus across the globe. While the health of women, particularly in countries with a poor record in violence against women and health of women, continue to overlook the health-related needs of women, particularly working women who continue to work from home and do household chores at the same time. Several programs promoting health of women in both rural and urban areas have come to standstill. However, once tings return to normal, it is expected that there will renewed activities pertaining to promotion of women’s health, which is likely to bolster growth of the global women’s health market in the years to come.
Some of the leading firms in the global women’s health market comprise Apothecus Pharmaceutical Corporation, Ferring Pharmaceuticals, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd, Lupin Pharmaceuticals, Inc., and Eli Lilly and Company. These companies are making use of various business strategies such as regional expansion, research and development activities for new products, and merger and acquisitions.
Rising Government Initiatives and Awareness to Shoot Up Demand in the Market
There has been a rise in the population of elderly women, i.e. women who are aged above 60 years, introduction of novel treatments and medicines for women, and augmented adoption of unhealthy lifestyle. These factors play significant role in boosting the global women’s health market over the tenure of assessment. In addition to that, favorable government policies, such as Indira Gandhi Matritva Sahyog Yojana in India to monitor the health of a mother, have been introduced to better the condition of women’s health. Government schemes are also aimed at raising the level of awareness about the health of women. Prevalence of such government schemes are likely to work in favor of the growth of the global women’s health market in the years to come.
Women are more vulnerable to diseases like obesity, depression, menstrual health-related disorders, anemia, osteoarthritis, and osteoporosis. There has been wide prevalence of these conditions amongst women and the incidences are rising with many of these conditions beginning quite early, such as osteoarthritis affecting women as young as 30 years. Rising prevalence of these medical conditions is likely to augur well for the global women’s health market for the period of analysis, from 2017 to 2030.
According to the findings of International Osteoporosis Foundation (IOF), a nongovernmental organization based out of Switzerland, incidences of osteoporosis amongst women is likely to reach a figure of 680 million by 2050. IOF is tasked with the treatment, diagnosis, and prevention of osteoporosis across the globe. Besides, mental illnesses, cardiovascular diseases, and breast cancer is likely to substantially add to the burden of non-communicable diseases amongst women. Most women are likely to undergo menopause after the age of 50, which creates hormonal changes and leave an undesirable impact of the quality of life of women. Many of the menopausal women experience hot flashes. The Society of Obstetricians and Gynecologists of Canada (SOGC), national medical society in Canada, presented an estimation that indicates at around 85.0% of women will suffer from at one of the side effects of menopause, which could be irritability or lack or interrupted sleep, and mood swings.
In addition to that, there have been changes in the dietary habits of women as well. More women have taken up consumption of alcohol and smoking, stress at work and home, frequent eating out and consumption of ready to eat food items have all contributed toward the deterioration of health of women. Change in lifestyle habits have caused hormonal imbalance and fertility issues in women, which is likely to support expansion of the global women’s health market in the enar future. These factors are estimated to promote growth of the global women’s health market in the years to come. Polycystic ovarian syndrome (PCOS), endometriosis, and ovulation problems are some of the major problems affecting the health of women.
Driven by the US, North America to Present Lucrative Growth Opportunities
It is estimated that North America, driven by the US, is likely to remain at the forefront of the growth of the global women’s health market over the tenure of assessment, from 2017 to 2030. Increased prevalence of women’s health therapeutics, thanks to the high investment made by both government and private agencies for drug research. These research and development activities have led to the invention of several advanced and sophisticated treatments for women, which is likely to support growth of the women’s health market in North America. In addition there has an increased focus on cancer care for women, which is likely to drive the market in the region. Presence of leading biotechnology and pharmaceutical firms in the region is another growth factor for the women’s health market in the region.
With the presence of a large untapped market, rise in government initiatives, and increasing awareness about the health of women are likely to offer rapid growth opportunities for the women’s health market in Asia Pacific in the years to come
Some of the prominent players in the Women’s Health Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Women’s Health market
Treatment Type
Disease Indication
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Women’s Health Market Study:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Acronyms Used
2.3. Research Methodology
3. Executive Summary
3.1. Global Women’s Health Market Snapshot
4. Market Overview
4.1. Market Overview
4.2. Market Opportunity Map
4.3. Key Industry Events
4.4. Global Women’s Health Market Size (US$ Mn) Forecast, 2017–2030
4.5. Global Women’s Health Market Outlook
4.6. Pipeline Analysis
4.7. Key Trends
4.8. Government Initiatives/Key Investments Assessment
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
6. Global Women’s Health Market Analysis, by Treatment Type
6.1. Introduction
6.2. Key Insights
6.3. Global Women’s Health Market Value Share Analysis, by Treatment Type
6.4. Global Women’s Health Market Forecast, by Treatment Type
6.4.1. Hormonal
6.4.1.1. Estrogen
6.4.1.2. Progestin
6.4.1.3. Combination
6.4.1.4. Parathyroid
6.4.1.5. Thyroid
6.4.1.6. Others
6.4.2. Non-Hormonal
6.4.2.1. Targeted Drugs
6.4.2.2. Antibiotics
6.4.2.3. Biphosphonates
6.4.2.4. Others
6.5. Global Women’s Health Market Attractiveness Analysis, by Treatment Type
6.6. Key Trends
7. Global Women’s Health Market Analysis, by Disease Indication
7.1. Introduction
7.2. Key Insights
7.3. Global Women’s Health Market Value Share Analysis, by Treatment Type
7.4. Global Women’s Health Market Forecast, by Treatment Type
7.4.1. Cancer
7.4.1.1. Breast Cancer
7.4.1.2. Cervical Cancer
7.4.1.3. Ovarian Cancer
7.4.2. Hypothyroidism
7.4.3. Menopause
7.4.4. Osteoporosis
7.4.5. Contraceptive
7.4.6. Uterine Fibroid
7.4.7. Urinary Tract Infection
7.5. Global Women’s Health Market Attractiveness Analysis, by Treatment Type
7.6. Key Trends
8. Global Women’s Health Market Analysis, by Region
8.1. Global Women’s Health Market Value Share Analysis, by Region
8.2. Global Women’s Health Market Forecast, by Region, 2017–2030
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
9. North America Women’s Health Market Analysis
9.1. North America Women’s Health Market Overview
9.2. North America Women’s Health Market Value Share Analysis, by Treatment Type
9.3. North America Women’s Health Market Value Share Analysis, by Disease Indication
9.4. North America Women’s Health Market Value Share Analysis, by Country
9.5. North America Women’s Health Market Forecast, by Treatment Type
9.5.1. Hormonal
9.5.1.1. Estrogen
9.5.1.2. Progestin
9.5.1.3. Combination
9.5.1.4. Parathyroid
9.5.1.5. Thyroid
9.5.1.6. Others
9.5.2. Non-Hormonal
9.5.2.1. Targeted Drugs
9.5.2.2. Antibiotics
9.5.2.3. Biphosphonates
9.5.2.4. Others
9.6. North America Women’s Health Market Forecast, by Disease Indication
9.6.1. Cancer
9.6.1.1. Breast Cancer
9.6.1.2. Cervical Cancer
9.6.1.3. Ovarian Cancer
9.6.2. Hypothyroidism
9.6.3. Menopause
9.6.4. Osteoporosis
9.6.5. Contraceptive
9.6.6. Uterine Fibroid
9.6.7. Urinary Tract Infection
9.7. North America Women’s Health Market Forecast, by Country
9.7.1. United States
9.7.2. Canada
9.8. North America Women’s Health Market Attractiveness Analysis,
9.8.1. By Treatment Type
9.8.2. By Disease Indication
9.8.3. By Country
9.9. North America – Key Trends
10. Europe Women’s Health Market Analysis
10.1. Europe Women’s Health Market Overview
10.2. Europe Women’s Health Market Value Share Analysis, by Treatment Type
10.3. Europe Women’s Health Market Value Share Analysis, by Disease Indication
10.4. Europe Women’s Health Market Value Share Analysis, by Country
10.5. Europe Women’s Health Market Forecast, by Treatment Type
10.5.1. Hormonal
10.5.1.1. Estrogen
10.5.1.2. Progestin
10.5.1.3. Combination
10.5.1.4. Parathyroid
10.5.1.5. Thyroid
10.5.1.6. Others
10.5.2. Non-Hormonal
10.5.2.1. Targeted Drugs
10.5.2.2. Antibiotics
10.5.2.3. Biphosphonates
10.5.2.4. Others
10.6. Europe Women’s Health Market Forecast, by Disease Indication
10.6.1. Cancer
10.6.1.1. Breast Cancer
10.6.1.2. Cervical Cancer
10.6.1.3. Ovarian Cancer
10.6.2. Hypothyroidism
10.6.3. Menopause
10.6.4. Osteoporosis
10.6.5. Contraceptive
10.6.6. Uterine Fibroid
10.6.7. Urinary Tract Infection
10.7. Europe Women’s Health Market Forecast, by Country / Sub-region
10.7.1. UK
10.7.2. Germany
10.7.3. France
10.7.4. Italy
10.7.5. Spain
10.7.6. Rest of Europe
10.8. Europe Women’s Health Market Attractiveness Analysis
10.8.1. By Treatment Type
10.8.2. By Disease Indication
10.8.3. By Country / Sub-region
10.9. Europe – Key Trends
11. Asia Pacific Women’s Health Market Analysis
11.1. Asia Pacific Women’s Health Market Overview
11.2. Asia Pacific Women’s Health Market Value Share Analysis, by Treatment Type
11.3. Asia Pacific Women’s Health Market Value Share Analysis, by Disease Indication
11.4. Asia Pacific Women’s Health Market Value Share Analysis, by Country
11.5. Asia Pacific Women’s Health Market Forecast, by Treatment Type
11.5.1. Hormonal
11.5.1.1. Estrogen
11.5.1.2. Progestin
11.5.1.3. Combination
11.5.1.4. Parathyroid
11.5.1.5. Thyroid
11.5.1.6. Others
11.5.2. Non-Hormonal
11.5.2.1. Targeted Drugs
11.5.2.2. Antibiotics
11.5.2.3. Biphosphonates
11.5.2.4. Others
11.6. Asia Pacific Women’s Health Market Forecast, by Disease Indication
11.6.1. Cancer
11.6.1.1. Breast Cancer
11.6.1.2. Cervical Cancer
11.6.1.3. Ovarian Cancer
11.6.2. Hypothyroidism
11.6.3. Menopause
11.6.4. Osteoporosis
11.6.5. Contraceptive
11.6.6. Uterine Fibroid
11.6.7. Urinary Tract Infection
11.7. Asia Pacific Women’s Health Market Forecast, by Country / Sub-region
11.7.1. China
11.7.2. Japan
11.7.3. India
11.7.4. Australia
11.7.5. Rest of APAC
11.8. Asia Pacific Women’s Health Market Attractiveness Analysis
11.8.1. By Treatment Type
11.8.2. By Disease Indication
11.8.3. By Country / Sub-region
11.9. Asia Pacific – Key Trends
12. Latin America Women’s Health Market Analysis
12.1. Latin America Women’s Health Market Overview
12.2. Latin America Women’s Health Market Value Share Analysis, by Treatment Type
12.3. Latin America Women’s Health Market Value Share Analysis, by Disease Indication
12.4. Latin America Women’s Health Market Value Share Analysis, by Country
12.5. Latin America Women’s Health Market Forecast, by Treatment Type
12.5.1. Hormonal
12.5.1.1. Estrogen
12.5.1.2. Progestin
12.5.1.3. Combination
12.5.1.4. Parathyroid
12.5.1.5. Thyroid
12.5.1.6. Others
12.5.2. Non-Hormonal
12.5.2.1. Targeted Drugs
12.5.2.2. Antibiotics
12.5.2.3. Biphosphonates
12.5.2.4. Others
12.6. Latin America Women’s Health Market Forecast, by Disease Indication
12.6.1. Cancer
12.6.1.1. Breast Cancer
12.6.1.2. Cervical Cancer
12.6.1.3. Ovarian Cancer
12.6.2. Hypothyroidism
12.6.3. Menopause
12.6.4. Osteoporosis
12.6.5. Contraceptive
12.6.6. Uterine Fibroid
12.6.7. Urinary Tract Infection
12.7. Latin America Women’s Health Market Forecast, by Country / Sub-region
12.7.1. Brazil
12.7.2. Mexico
12.7.3. Rest of Latin America
12.8. Latin America Women’s Health Market Attractiveness Analysis
12.8.1. By Treatment Type
12.8.2. By Disease Indication
12.8.3. By Country / Sub-region
12.9. Latin America – Key Trends
13. Middle East & Africa Women’s Health Market Analysis
13.1. Middle East & Africa Women’s Health Market Overview
13.2. Middle East & Africa Women’s Health Market Value Share Analysis, by Treatment Type
13.3. Middle East & Africa Women’s Health Market Value Share Analysis, by Disease Indication
13.4. Middle East & Africa Women’s Health Market Value Share Analysis, by Country
13.5. Middle East & Africa Women’s Health Market Forecast, by Treatment Type
13.5.1. Hormonal
13.5.1.1. Estrogen
13.5.1.2. Progestin
13.5.1.3. Combination
13.5.1.4. Parathyroid
13.5.1.5. Thyroid
13.5.1.6. Others
13.5.2. Non-Hormonal
13.5.2.1. Targeted Drugs
13.5.2.2. Antibiotics
13.5.2.3. Biphosphonates
13.5.2.4. Others
13.6. Middle East & Africa Women’s Health Market Forecast, by Disease Indication
13.6.1. Cancer
13.6.1.1. Breast Cancer
13.6.1.2. Cervical Cancer
13.6.1.3. Ovarian Cancer
13.6.2. Hypothyroidism
13.6.3. Menopause
13.6.4. Osteoporosis
13.6.5. Contraceptive
13.6.6. Uterine Fibroid
13.6.7. Urinary Tract Infection
13.7. Middle East & Africa Women’s Health Market Forecast, by Country / Sub-region
13.7.1. GCC Countries
13.7.2. South Africa
13.7.3. Rest of Middle East & Africa
13.8. Middle East & Africa Women’s Health Market Attractiveness Analysis
13.8.1. By Treatment Type
13.8.2. By Disease Indication
13.8.3. By Country / Sub-region
13.9. Middle East & Africa – Key Trends
14. Competition Landscape
14.1. Competitive Positioning
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Eli Lilly and Company
14.3.1.1. Overview (HQ, Employee Strength, Business Segments)
14.3.1.2. Financials
14.3.1.3. Recent Developments
14.3.1.4. Strategy
14.3.2. Novartis AG
14.3.2.1. Overview (HQ, Employee Strength, Business Segments)
14.3.2.2. Financials
14.3.2.3. Recent Developments
14.3.2.4. Strategy
14.3.3. Pfizer, Inc.
14.3.3.1. Overview (HQ, Employee Strength, Business Segments)
14.3.3.2. Financials
14.3.3.3. Recent Developments
14.3.3.4. Strategy
14.3.4. Merck & Co., Inc.
14.3.4.1. Overview (HQ, Employee Strength, Business Segments)
14.3.4.2. Financials
14.3.4.3. Recent Developments
14.3.4.4. Strategy
14.3.5. Novo Nordisk A/S
14.3.5.1. Overview (HQ, Employee Strength, Business Segments)
14.3.5.2. Financials
14.3.5.3. Recent Developments
14.3.5.4. Strategy
14.3.6. Amgen Inc.
14.3.6.1. Overview (HQ, Employee Strength, Business Segments)
14.3.6.2. Financials
14.3.6.3. Recent Developments
14.3.6.4. Strategy
14.3.7. AstraZeneca
14.3.7.1. Overview (HQ, Employee Strength, Business Segments)
14.3.7.2. Financials
14.3.7.3. Recent Developments
14.3.7.4. Strategy
14.3.8. F. Hoffmann-La Roche Ltd.
14.3.8.1. Overview (HQ, Employee Strength, Business Segments)
14.3.8.2. Financials
14.3.8.3. Recent Developments
14.3.8.4. Strategy
14.3.9. Sanofi
14.3.9.1. Overview (HQ, Employee Strength, Business Segments)
14.3.9.2. Financials
14.3.9.3. Recent Developments
14.3.9.4. Strategy
14.3.10. Allergan Plc
14.3.10.1. Overview (HQ, Employee Strength, Business Segments)
14.3.10.2. Financials
14.3.10.3. Recent Developments
14.3.10.4. Strategy
14.3.11. GlaxoSmithKline plc
14.3.11.1. Overview (HQ, Employee Strength, Business Segments)
14.3.11.2. Financials
14.3.11.3. Recent Developments
14.3.11.4. Strategy
14.3.12. Lupin Pharmaceuticals, Inc.
14.3.12.1. Overview (HQ, Employee Strength, Business Segments)
14.3.12.2. Financials
14.3.12.3. Recent Developments
14.3.12.4. Strategy
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers